https://www.lymectn.org/Pilot.aspx

CTN Tick-borne Disease Pilot Treatment Study Award

We are happy to announce that the Clinical Trials Network established with a grant from the Steven & Alexandra Cohen Foundation to Columbia University announces the third round of Pilot Study Proposal submissions (January 15 to March 15, 2023).

The Clinical Trials Network welcomes clinicians, researchers, and investigators from academic institutions to submit proposals. The proposals are typically 1-3 pages in length, but longer proposals are accepted for review. The CTN’s goal is to support the conduct of small-scale human treatment studies related to treatment of Lyme and other tick-related diseases. These small pilot studies are conducted to determine whether future larger investigations are warranted. Pilot studies often assess safety and feasibility, are exploratory in nature, and are not meant to answer the same questions as larger randomized control trials.

The CTN Study Review Committee will review submissions for consideration for further development into a pilot study; each pilot study will be conducted at one of the CTN investigation sites. The CTN has funding to support 1-2 small pilot studies each year.

Current CTN network affiliates include investigators from Columbia University Irving Medical Center in New York City, Johns Hopkins University Medical Center in Baltimore Maryland, and Children’s National Hospital in Washington D.C. The CTN Study Review Committee includes the core CTN members, clinical research experts, and academic and community clinicians. Results of the CTN pilot studies – if favorable – will lead to consideration for larger Randomized Controlled Trials.

The deadline for the first round of submissions for treatment research ideas from the research scientists and clinicians is March 15, 2023. The submission period opens January 15, 2023.

We thank all clinicians and investigators in advance for participation in this process, as your proposal may lead to a transformative study.

________________
For more:

The fear here is that if this leads to human trials, only those who test positive with an EM rash will qualify, persistent infection will be once again denied, and the continued use of PTLDS will be utilized which will once more omit the sickest patients that are seronegative and without the rash.  This affects everything and hasn’t changed in 40 years.  The entire premise and paradigm is wrong but continues to be utilized in tick-borne disease research.

%d bloggers like this: